The standard lipid profile has an enormous scientific evidence base and has provided simple clinical lipid-altering goals focused on low-density lipoprotein (LDL) cholesterol that have been shown to reduce coronary heart disease. Its limitations in estimating LDL cholesterol are well known: increasing inaccuracies in the nonfasting state, in individuals with triglycerides greater than 200 to 400 mg/dL, and as an accurate measure of LDL particle risk in size and concentration. Until studies are done comparing the benefit of targeting LDL particle concentration and size versus ever lower LDL cholesterol concentration, widespread clinical use of continuing revisions of the standard lipid profile goals will continue to remain one of the giant clinical and public health achievements of the last 50 years.